Updated on 1 June 2026
program available on the platform, add your proposals Franchise health zone
Prezes i dyrektor projektu at MŚP
Warszawa, Poland
About
Partner Collaboration – Innovative Energy Solutions . We are a manufacturer of advanced energy technologies, specializing in mobile energy sources and solutions for crisis situations. Our products are based on R&D&I (Research, Development, and Innovation), tested prototypes, and extensive experience in the Deep Tech industry . Privious collaboration and development of international programs with a large European pharmaceutical company in Poland. Extensive knowledge of the scope of work and program implementation.
Stage
- Planning
Topic
- IHI Topic 1: IHI European healthcare incubator network
- IHI Topic 2: An AI foundation toxicology model and framework to support waiving a second species in drug safety studies
- HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research (RIA)
- HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care (RIA)
- HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients (RIA)
- HORIZON_MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- HORIZON_MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
Type
- Consortium looking for partners
Attached files
Organisation
Similar opportunities
Project cooperation
PanGI Landmark Graph™ – Whole-Tract Capsule Intelligence
- IHI Topic 1: IHI European healthcare incubator network
- Partner offering expertise and is looking for a consortium
- IHI Topic 3: Decode the immuno-science of age-related mediated diseases
- HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care (RIA)
- HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research (RIA)
- HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients (RIA)
- HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease (RIA)
- HORIZON_MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- IHI Topic 2: An AI foundation toxicology model and framework to support waiving a second species in drug safety studies
- HORIZON-MISS-2026-02-CANCER-06: Development of a research capacity building programme on cancer with and for Ukraine (RIA)
- HORIZON_MISS-2027-02-CANCER-02 Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
- HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers (RIA)
- HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC) (IA)
- HORIZON_MISS-2027-02-CANCER-06 Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies
- HORIZON_MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- HORIZON_MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
- HORIZON_MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Miadreza Shafiekhah
Head of Research and Innovation at Nowocert
Dublin, Ireland
Project cooperation
CortexView Imaging Intelligence™ – AI-Enhanced Acquisition and Diagnosis
- IHI Topic 1: IHI European healthcare incubator network
- Partner offering expertise and is looking for a consortium
- IHI Topic 3: Decode the immuno-science of age-related mediated diseases
- HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care (RIA)
- HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research (RIA)
- HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients (RIA)
- HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease (RIA)
- HORIZON_MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- IHI Topic 2: An AI foundation toxicology model and framework to support waiving a second species in drug safety studies
- HORIZON-MISS-2026-02-CANCER-06: Development of a research capacity building programme on cancer with and for Ukraine (RIA)
- HORIZON_MISS-2027-02-CANCER-02 Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
- HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers (RIA)
- HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC) (IA)
- HORIZON_MISS-2027-02-CANCER-06 Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies
- HORIZON_MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- HORIZON_MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
- HORIZON_MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Miadreza Shafiekhah
Head of Research and Innovation at Nowocert
Dublin, Ireland
Project cooperation
MaternAI LiveCare™ – Continuous Lifestyle and Maternal Health Intelligence
- IHI Topic 1: IHI European healthcare incubator network
- Partner offering expertise and is looking for a consortium
- IHI Topic 3: Decode the immuno-science of age-related mediated diseases
- HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care (RIA)
- HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research (RIA)
- HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients (RIA)
- HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease (RIA)
- HORIZON_MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- IHI Topic 2: An AI foundation toxicology model and framework to support waiving a second species in drug safety studies
- HORIZON-MISS-2026-02-CANCER-06: Development of a research capacity building programme on cancer with and for Ukraine (RIA)
- HORIZON_MISS-2027-02-CANCER-02 Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
- HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers (RIA)
- HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC) (IA)
- HORIZON_MISS-2027-02-CANCER-06 Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies
- HORIZON_MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- HORIZON_MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
- HORIZON_MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Miadreza Shafiekhah
Head of Research and Innovation at Nowocert
Dublin, Ireland